Phenylbiguanide (PBG) is a 5-HT3 agonist used to study the role of 5-HT3 receptors in the central nervous system.[1] It has been found to trigger dopamine release in the nucleus accumbens of rats.[2]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.002.726 |
Chemical and physical data | |
Formula | C8H11N5 |
Molar mass | 177.211 g·mol−1 |
3D model (JSmol) | |
Melting point | 135–142 °C (275–288 °F) |
| |
|
Derivatives
edit- Phenylbiguanide is used to make amanozine and benfosformin.[citation needed]
References
edit- ^ Higgins GA, Joharchi N, Sellers EM (March 1993). "Behavioral effects of the 5-hydroxytryptamine3 receptor agonists 1-phenylbiguanide and m-chlorophenylbiguanide in rats". The Journal of Pharmacology and Experimental Therapeutics. 264 (3). Journal of Pharmacology and Experimental Therapeutics: 1440–9. PMID 8450478.
- ^ Chen JP, van Praag HM, Gardner EL (March 1991). "Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens". Brain Research. 543 (2). Brain Research.: 354–7. doi:10.1016/0006-8993(91)90050-6. PMID 1711914. S2CID 37426395.